The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR. PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP. Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial. The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging. A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging. Enzalutamide combined with leuprolide led to higher rates of MFS than leuprolide alone. ArteraAI Prostate—a multimodal, AI-derived prognostic test—was successfully validated in the phase 3 STAMPEDE trials. New understandings of PROs related to enzalutamide-plus-leuprolide-acetate treatment for high-risk BCR nmHSPC. According to new data, concerns surrounding the efficacy of 19-20 Gy single-dose HDR-BT as a monotherapy may be unfounded. While the low-dose arm required more salvage therapy, dose-escalated RT resulted in lower rates of DM. Blinded, independent review revealed MFS insights for patients who received radiotherapy before treatment for BCR PC. Intermediate-risk PC can be treated as effectively with SBRT as with conventional radiation, according to 5-year results. Bladder cancers that develop after radiation tend to be more aggressive and are more likely to be sarcomatoid variant. Higher tumor fraction after chemohormonal therapy was also linked to aggressive pathologic features and poor outcomes. Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative. Utilizing BCR as a replacement measurement for OS in patients with localized prostate cancer is a controversial topic. The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques. A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status. What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI? An AI-based model predicts which patients with localized prostate cancer would better benefit from the use of ADT.